Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy

Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck

(2013) Jean-Pascal Machiels et al.   INVESTIGATIONAL NEW DRUGS

Simultaneous TLR2 inhibition and TLR9 activation synergistically suppress tumor metastasis in mice

(2012) Jun Yan et al.   ACTA PHARMACOLOGICA SINICA

Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease

(2012) Thomas Yau et al.   INVESTIGATIONAL NEW DRUGS

Anticancer TLR agonists on the ropes

(2012) Malini Guha   NATURE REVIEWS DRUG DISCOVERY

A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer

(2011) C. Manegold et al.   ANNALS OF ONCOLOGY

In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study

(2011) Y. H. Kim et al.   BLOOD

Cancer statistics, 2011

(2011) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

An integrative view of the pathophysiological events leading to cisplatin nephrotoxicity

(2011) Penélope D. Sánchez-González et al.   CRITICAL REVIEWS IN TOXICOLOGY

Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

(2011) Vera Hirsh et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial

(2011) Roy S Herbst et al.   LANCET

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer

(2010) Andrew H. Ko et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Harnessing Innate Immunity to Suppress Lymphoma

(2010) Freda K. Stevenson et al.   JOURNAL OF CLINICAL ONCOLOGY

In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study

(2010) Joshua D. Brody et al.   JOURNAL OF CLINICAL ONCOLOGY

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study

(2009) Ezra EW Cohen et al.   LANCET ONCOLOGY

Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer

(2008) Martin Reck et al.   LUNG CANCER

Considerations for Second-Line Therapy of Non-Small Cell Lung Cancer

(2008) T. E. Stinchcombe et al.   ONCOLOGIST